After failing to reach a reimbursement agreement with French officials on its cystic fibrosis drug Orkambi, Vertex has cancelled plans to test an investigational triple combination at several sites in the country.Original Article
Vertex cancels plans for CF triple combo testing in France, citing failed Orkambi negotiations
